Aspiration and Biopsy Needles Market

Numerous hematologic illnesses can be diagnosed through bone marrow aspiration and biopsies, which are frequently done in both inpatient and outpatient settings. This treatment is commonly performed using both the palpation-guided and computed-tomography-guided procedures, which offer low rates of complications and good diagnostic accuracy. The right way to execute a bone marrow aspiration and biopsy is described in this activity, which also emphasizes the importance of the interprofessional team in the patient's care.
As a gold standard for the investigation and final diagnosis of hematologic malignancies, bone marrow aspirations and biopsies are still performed. These techniques are less complicated to use, avoid more intrusive procedures, and can provide an accurate diagnosis in a reasonable length of time. A nontraumatic experience for the patient as well as a fast route to diagnosis and treatment are made possible by the short duration of the procedure, the possibility of avoiding sedation or general anesthesia, and the ability to do it as an outpatient.
 

Key Players
Argon Medical Devices (United States)
Becton Dickinson (United States)
Boston Scientific Corporation (United States)
Cardinal Health (United States)
CONMED Corporation (United States)
Cook Group Incorporated (United States)
HAKKO (United States)
INRAD Inc. (United States)
Medtronic Plc (United States)
Merit Medical Systems (United States)
Olympus (Japan)
Remington Medical (United States)
Somatex Medical Technologies (Germany)
Stryker Corporation (United States)
 

Segmentation

•    By Type
o    Core-needle
o    Fine-needle
o    Laparoscopic aspiration needles
 

•    By End User
o    Hospitals
o    Clinics
o    Research Laboratories

•    By Application
o    Breast
o    Thyroid
o    Suspicious lymph nodes
o    Suspicious skin masses

Market Dynamics

Driver 

• Compared to open biopsy, fine needle aspiration (FNA) can evaluate neck masses more quickly, saving time and money while also perhaps improving health outcomes through early detection and treatment. Aspiration and biopsy needles are essential for cancer detection and staging, hence the growing incidence of the disease is a major factor driving the market for these instruments. The implantation of malignant cells along the needle route is an incredibly unusual but possible consequence of malignant lesion biopsy by percutaneous needle aspiration. Recent years have seen an increase in interest in percutaneous fine-needle aspiration biopsy (FNAB) for the cytologic detection of bronchogenic cancer due to its minimal morbidity, ease of administration, and good diagnostic yield.
• Necessity for aspiration and biopsy needles in diagnostic procedures has increased due to the aging population's greater susceptibility to many diseases, including cancer. Fine-needle aspiration and biopsy should be performed on adult thyroid and salivary gland lesions. It is also necessary to carry out this diagnostic procedure if a neck mass continues for more than four to six weeks. When performed by skilled professionals, fine-needle aspiration and biopsy have sensitivity and specificity that above 90%. 
   

Restraints

• Even though biopsies are normally safe, there is a chance of consequences including bleeding and infection, which can be limiting in some circumstances. Fine-needle aspiration problems are rather uncommon. Due to the needle's small size, bleeding, injury to adjacent structures, and formation of fistulas are all reduced.
• Patients who are coagulopathic for any reason are most at risk for bleeding. Usually, physical compression stops the bleeding in these patients. The other significant risk is inadvertently seeding tissue planes with cancerous or infected cells when inserting the needle to aspirate the desired region. Because of this, it's critical to evaluate whether a fine-needle aspiration is required to direct treatment or if final treatment should be pursued in the event that one is not. Manufacturers may face difficulties adhering to stringent regulatory requirements for medical equipment, which could impede the expansion of the industry.
   

Opportunity

• Novel frameless MRI-guided robotic device that has the benefit of allowing the biopsy needle to do both tissue suction and lesion ablation utilizing high-intensity therapeutic ultrasound in situations of localized malignant tumors with a single catheter insertion. This new technology helps with diagnostics and, if a tumor is found to be malignant, its size enables ablation of the lesion in a single surgical procedure. It could shorten hospital stays and lessen the surgical morbidity of repeated procedures. Tissue sampling is becoming more accurate and efficient thanks to ongoing developments in needle technology, such as the creation of vacuum-assisted biopsy equipment.
• Ultrasound-assisted medical needle activation has been shown to cause tissue movement, which may aid in localizing the needle under Doppler ultrasonography, or decrease the needle's penetration resistance, which may lessen discomfort associated with the needle's insertion through the skin.
   

Recent Industry Insight

• On Mar. 2021, FDA Clears Olympus' Narrow Band Imaging (NBI) for Use in Assessing Colonic Lesions
• On January 2021, Hologic to Acquire SOMATEX, Leader in Biopsy Site Markers and Localization Technologies

Key Target Audience

• End User
• Potential Investors
• New Entrants
• Innovation and R&D
• Suppliers and Manufacturers
• Others